Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems by Cunnea, P & Stronach, EA
REVIEW ARTICLE
published: 17 April 2014
doi: 10.3389/fonc.2014.00081
Modeling platinum sensitive and resistant high-grade
serous ovarian cancer: development and applications of
experimental systems
Paula Cunnea and Euan A. Stronach*
Molecular Therapeutics Laboratory, Ovarian Cancer Action Research Centre, Institute of Reproductive and Developmental Biology, Department of Cancer and
Surgery, Imperial College London, London, UK
Edited by:
Viive Maarika Howell, University of
Sydney, Australia
Reviewed by:
Amir Jazaeri, University of Virginia,
USA
MarkWilliam Nachtigal, University of
Manitoba, Canada
*Correspondence:
Euan A. Stronach, Molecular
Therapeutics Laboratory, Ovarian
Cancer Action Research Centre,
Institute of Reproductive and
Developmental Biology, Department
of Cancer and Surgery, Imperial
College London, 4th Floor
Laboratories, Du Cane Road, London
W12 ONN, UK
e-mail: e.stronach@imperial.ac.uk
High-grade serous ovarian cancer remains the most common sub-type of ovarian cancer
and, characterized by high degrees of genomic instability and heterogeneity, is typified by
a transition from early response to acquired resistance to platinum-based chemotherapy.
Conventional models for the study of ovarian cancer have been largely limited to a set of
relatively poorly characterized immortalized cell lines and recent studies have called into
question the validity of some of these as reliable models. Here, we review new approaches
and models systems that take into account advances in our understanding of ovarian cancer
biology and advances in the technology available for their generation and study. We discuss
primary cell models, 2D, 3D, and organotypic models, and “paired” sample approaches that
capture the evolution of chemotherapy failure within single cases. We also overview new
methods for non-invasive collection of representative tumor material from blood samples.
Adoption of such methods and models will improve the quality and clinical relevance of
ovarian cancer research.
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INTRODUCTION
Ovarian cancer is currently the fourth leading cause of can-
cer deaths in women in the UK and the most common cause
of gynecological cancer deaths, with approximately 4300 deaths
from the disease in 2011 alone (http://www.cancerresearchuk.org/
cancer-info/cancerstats/types/ovary/). The mortality rate for ovar-
ian cancer is high as disease largely remains undetected, due to
the vague nature of its symptoms and lack of reliable biomark-
ers, until patients finally present with high volume, disseminated
disease. The current standard care for ovarian cancer involves
cytoreductive surgery followed by combination chemotherapy
with platinum compounds and taxanes. However, chemoresistant
disease typically recurs in patients, most commonly in the high-
grade serous (HGS) sub-type, with a low 5-year average survival
rate of less than 40%. Ovarian cancer is a very heterogeneous dis-
ease, with the four most common sub-types of epithelial ovarian
cancer (EOC) being serous, endometrioid, mucinous, and clear
cell. They can be further divided into low-grade type I (relatively
resistant to platinum-based chemotherapy) and the more com-
mon high-grade type II (more responsive to initial platinum-based
chemotherapy but paradoxically poorer prognosis) tumors. Type I
tumors, including low-grade serous and endometrioid, mucinous
and clear cell histotypes, make up 10–20% of EOC, present at early
stage (FIGO I-II), genetically have near normal gene copy number,
are usually wild type for p53 and harbor characteristic mutations
in genes such as Ras (mucinous and low-grade serous) and PTEN
(endometrioid) among others. Type II lesions including HGS can-
cers, undifferentiated cancers, carcinosarcomas, and high-grade
endometrioid, typically present at advanced stage (FIGO III–IV),
are characterized by high genomic instability (near 50% deficiency
in Homologous Recombination repair), near 100% p53 mutation
rate, and have extensive DNA copy number changes (1).
The development of platinum-resistant disease is a critical
and poorly understood problem in ovarian cancer, especially in
the most prevalent HGS sub-type. Broadly, two potential mod-
els for the evolution of chemoresistance in HGSOC are proposed;
one suggests that treatment with DNA-damaging platinum ther-
apy causes mutations that give rise to resistance and the other
suggests that genetically heterogeneous tumor clones exist prior
to chemotherapy and subsequent treatment preferentially selects
resistant clones for survival while platinum sensitive clones are
eradicated by chemotherapy treatment (2). A genomic analysis of
cell lines derived from three serous ovarian cancer patients, both
before and after acquisition of clinical platinum resistance, indi-
cated that in addition to shared genomic features, sensitive and
resistant tumor cells from the same patient also exhibit mutu-
ally exclusive genomic characteristics, indicating that rather than
a direct linear evolution of resistance from sensitive disease in
response to platinum challenge, platinum-resistant clones are
present from the outset within the sensitive presenting tumor (3).
However, the bulk of research in this area has suffered due to the
lack of appropriate models for developing effective therapeutic
solutions to counter chemoresistance; and an inadequate sam-
pling of tumor tissue, potentially missing the rich heterogeneity of
HGS disease and hence the ability to study its underlying biology.
Furthermore, many mechanistic studies investigating platinum
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resistance have to date relied on cell lines in which platinum resis-
tance is derived in vitro, the mechanisms of which may have little
or no relevance in the clinical setting (4).
Therefore, there is an urgent need to develop new models of
platinum-resistant and refractory ovarian cancer to help improve
outcomes for patients with chemoresistant disease. In this review,
we will outline the procedures, technical challenges, and appli-
cations of modeling platinum-based chemoresistance in primary
tumor cell cultures derived from ascites and solid tumors; the
development of new immortalized cell lines and currently avail-
able cell line models of platinum-sensitive and -resistant HGS; and
alternative systems of capturing tumor biology and heterogeneity
in HGS disease.
DEVELOPMENT OF PRIMARY MODELS OF HGS DISEASE
The clinical relevance of cell line models is a topic that is often
debated. The use of established cell lines, while certainly not with-
out their merits, may misrepresent responses to targeted therapies
and users should research carefully the nature of the cell line mod-
els they chose, and how closely they relate to the clinical condition.
To uncover the molecular mechanisms driving EOC development
and treatment, suitable disease models must be available to faith-
fully mirror the disease in vitro and in vivo. For the study of drug
resistance, especially when testing novel therapies, ex vivo mod-
els or cell line models that closely mimic the in vivo situation are
required. The use of patient material such as ascites (a rich source
of tumor cells) or solid tumor allows us to derive primary tumor
cell cultures that closely resemble the patient situation, therefore
representing a more experimentally accurate model than poorly
characterized immortalized cell lines, often of uncertain origin.
Primary tumor cell cultures are kept for a relatively short period
of time and can be cumbersome to start and maintain in culture,
but can be developed into well-annotated secondary immortalized
cultures. Different methodologies have been developed for the iso-
lation of EOC tumor cells from ascites and solid tumors. Here, we
outline a number of recently published methods to retrieve and
culture EOC tumor cells, the methods for development of immor-
talized cell lines from primary cultures and options available for
3D cell culture systems that attempt to more closely model the
in vivo setting.
ISOLATION AND CULTURE OF EOC TUMOR CELLS FROM ASCITES
Ascites fluid can be a rich source of tumor cells that are highly
accessible following paracentesis from the patient. Isolation and
primary culturing of tumor cells from ascites have become more
widespread and several different methods have been established
to achieve this aim (5–8). A widely used protocol for the prop-
agation of EOC tumor cells was developed by Langdon et al.
(6, 9). Freshly drained ascites fluid, mixed with heparin to pre-
vent cell aggregation, is pelleted by centrifugation, resuspended
in PBS, and subjected to gradient centrifugation using histopaque
or Ficoll-hypaque to remove any contaminating erythrocytes. The
resulting interface layer is washed in PBS prior to culturing in
appropriate tissue culture media, monitored carefully for fibrob-
last or mesothelial cell contamination, with the EOC tumor cells
sub-cultured upon confluency (6, 9, 10). Alternatively, Shepherd
et al. mix ascites 1:1 with M199/MCDB105 growth medium and
monitor EOC tumor cell growth in culture, relying on EOC cells
adhering to the plastic and contaminating erythrocytes being
removed in the first set of media changes approximately 4 days
after initial seeding (7). Similarly, methodology favored by Mes-
Masson and colleagues directly mixes the EOC cells with growth
media with minimal manipulation of the ascites-derived EOC
cells (11–14). The different adherence rates of particular cells can
also be used to separate EOC tumor cells from ascites (15). In
this study, ascites cells were seeded onto low attachment plates
for 24 h, following which two distinct populations of cells were
observed: multicellular aggregates floating in media; and spindle-
like fibroblast cells adhered to the low attachment plates. Further
characterization identified the non-adherent cell population to be
epithelial cell adhesion molecule (EpCAM) and CA125 positive
EOC tumor cells (15), thus indicating that differential rates of
adherence to plastic can be used to minimize contamination from
other ascites cell types.
Different media can also influence the growth of primary tumor
cells. Originally optimized for the growth of primary ovarian sur-
face epithelial (OSE) cells (16), a combination of M199/MCDB105
media has been used for culturing primary ovarian tumor cells
derived from ascites or solid tumor (7, 11). Supplements such
as EGF and hydrocortisone have also been used in different cell
culture media preparations; however, use of these agents in cultur-
ing OSE cells have been shown to initiate EMT (17). Continuous
growth of primary ovarian tumor cells can also be achieved using
commonly used culture media RPMI or DMEM (9). Addition
of pre-cleared autologous ascites fluid to EOC cultures may aid in
enhanced growth of cultures (9). Successful establishment of ovar-
ian serous carcinoma cell lines has also occurred using serum-free
culture media (18, 19).
A significant problem that arises however in the growth of EOC
tumor cells following isolation from ascites is the presence of other
contaminating cells such as fibroblasts or mesothelial cells. Careful
monitoring of tumor cells in culture from any culturing technique
is required to prevent contamination of the cultures from these cell
types. Proliferation of fibroblasts will cease after a number of pas-
sages; however, if not contained from initial culturing, fibroblasts
can outgrow the tumor cells and take over the culture. Selective
trypsinization with low concentrations of trypsin can be used to
remove contaminating fibroblasts or mesothelial cells from pri-
mary cultures, as they tend to detach more rapidly from plastic
than tumor cells (6). However, this may need to be repeated several
times to maintain a fibroblast-free culture.
Recent advances have lead to the use of magnetic enrichment
for detection or purification of cells from fluid specimens (20). The
EpCAM (CD326) is a transmembrane glycoprotein expressed by
particular epithelial cell types in healthy individuals; however, it is
over-expressed in most carcinomas (21) and is a target in antibody-
based therapies, e.g., trifunctional bispecific antibody catumax-
omab was approved by the European Medicines Agency 2009 for
the treatment of malignant ascites (21–23). The over-expression
of EpCAM in carcinomas has been exploited in the develop-
ment of purification systems such as CD326 microbeads (from
Milteny Biotec, Germany) or BerEP4 Dynabeads (Life Technolo-
gies, USA) allowing for the enrichment or depletion of EpCAM
positive cell populations from fluid specimens such as ascites
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or pleural effusions. An advantage to selectively enriching EOC
tumor cell populations prior to culturing is reduced contamina-
tion from fibroblasts and other cell types in the initial culture, thus
not requiring monitoring for overgrowth of contaminating cell
populations. Immunofluorescent staining for EpCAM performed
on ascites cells (pre-cleared using histopaque-gradient centrifu-
gation) before and after EpCAM microbead purification can be
used to confirm highly enriched EpCAM positive EOC tumor
cell populations post purification (authors unpublished observa-
tions). However, when using this additional step for isolation of
EpCAM positive epithelial tumor cells, one must take into account
that tumor cells that do not express EpCAM or express EpCAM at
very low levels will be excluded, thus potentially losing important
sub-clones of tumor cells. Cells that have undergone EMT, such as
circulating tumor cells (CTCs), may have low or absent levels of
EpCAM so using such enrichment techniques may fail to isolate
these cell populations (24).
DISSOCIATION OF EOC TUMOR CELLS FROM SOLID TUMORS
Several laboratories over the previous decades have developed var-
ious methods for EOC tumor cell isolation from solid tumor and
metastatic deposits. Langdon et al. have advocated mechanical
dissociation of tumor fragments using crossed scalpels, with cell
suspensions filtered through sterile gauze to remove any remain-
ing cell clumps before placing in culture (6, 10). The laboratories
of Nachtigal and Mes-Masson have employed both mechanical
disruption of tumor tissue using cell scrapers and enzymatic dis-
ruption of tumor using collagenase and concluded that mechanical
dissociation was the more efficient method for their purposes
(13, 14). More recently, Sueblinvong and colleagues compared a
number of enzymes (collagenase A, hyaluronidase, and dispase
II) commonly used for tumor dissociation and digestion times
to mechanical disruption, examining viability and proliferation
of the isolated tumor cells, and determined that 30 minute incu-
bation with dispase II was optimal for dissociation of viable EOC
tumor cells for primary culture and downstream applications (25).
As with tumor cell cultures derived from ascites, careful monitor-
ing of tumor-derived EOC cells in culture is required to minimize
fibroblast contamination.
DEVELOPMENT OF IMMORTALIZED SECONDARY CELL LINES
Primary cell lines have the disadvantage that they are short lived
and may only be sub-cultured for days, weeks, or at most a num-
ber of months. A secondary immortalized cell line can be obtained
from a primary culture: these have the advantages in that one is
studying a pure and expandable population of tumor cells, uncon-
taminated with fibroblasts or other stromal cells, and are a contin-
uous source to be accessed repeatedly ad infinitum. Establishment
of a secondary culture can be achieved either by spontaneous
or induced transformation of cells, e.g., SV40 T antigen induced
immortalization. Spontaneous immortalization of cells can occur
as cells maintained in culture over time can overcome senescence
without the addition of exogenous agents to induce immortaliza-
tion (26). Recently, platinum sensitive and resistant HGSOC lines
were derived by Letourneau et al. and deemed to be immortal-
ized when passaged more than 50 times (13). Alternatively, cell
line models, such as the cisplatin-resistant HEY ovarian cancer
cell line, have been developed from xenografted ovarian tumors
passaged in immunologically deprived mice (27).
Normal controls of cancer tissues for comparative studies are
also required but spontaneous immortalization of cultured nor-
mal cells is extremely rare and in the case of normal breast
cells has only been observed in epithelial cells (28). In vitro
immortalization is therefore necessary to induce secondary cul-
tures of normal cells. Different methods have been employed
to overcome the growth arrest barrier including transduction of
viral oncogenes [reviewed in Ref. (28, 29)], radiation treatment
(30), or carcinogenic chemical treatment (31, 32): viral onco-
genic transformation methods have been used most commonly
and successfully. Immortalization of normal human OSE cells has
been induced using various methods, for example, using telom-
erase and temperature-sensitive SV40 large T antigen (33) and
more recently immortalization of fallopian tube secretory epithe-
lial cells (FTSEC) have been established by expressing human
telomerase reverse transcriptase and perturbing the p53 and pRb
tumor suppressor pathways (34). However, a caveat to the estab-
lishment of any secondary culture is that the cell clones that
survive and become immortalized may be derived from a sub-
population particularly well adapted to cell culture conditions,
but may not necessarily be the best representation of the actual
tumor.
3D MODEL SYSTEMS OF HGS DISEASE
The vast majority of data produced on ovarian cancer and thera-
peutic responses is based on 2D cell culture models, whether they
are ex vivo primary cells in short-term culture or immortalized cell
lines, which both have distinct advantages but ultimately do not
represent the three-dimensional nature of the human in vivo situ-
ation. Within the peritoneal cavity, transformed epithelial tumor
cells can freely disseminate and be carried by the flow of peri-
toneal fluid (35). Spheroids of tumor cells can adhere to peritoneal
mesothelial cells, anchor in the submesothelial matrix, and invade
to form secondary lesions (36, 37). Thus, mimicking this system of
adhesion, migration, and invasion in vitro, and thereby creating a
more physiologically relevant microenvironment, could improve
the concordance between predictions made in the laboratory and
the clinical situation.
The 3D cultures can be created using several different meth-
ods; culturing cells within extracellular matrix gels (38), on low-
adherent plastics (15) or non-adherent (polyHEMA)-coated tissue
culture plastics (39); hanging-drop culture methods (13, 40, 41);
spinner flasks (42); or rotary cell culture system (39). Recreat-
ing the 3D architecture of tissues and solid tumors using these
methods better recapitulates primary tumor architecture than 2D
monolayer culturing of cells. The 3D system could also be used
as a predictive preclinical model, treating tumor cells in this ex
vivo environment and determining response to therapy. Several
studies have emerged recently using 3D models to elucidate mech-
anisms of drug resistance in EOC (43–47). A large-scale study
using 3D models of 31 epithelial cell lines, compared their bio-
logical and molecular features with 2D cultures, and determined
their response rates to chemotherapy agents, with 3D cultures dif-
ferentially expressing adherens junction proteins (47), and in con-
cordance with previous studies, 3D cultures were frequently more
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chemoresistant than their 2D counterparts (43–46). Furthermore,
gene expression profiles of 3D cultured cells differ significantly
from their 2D profiles, with 3D cultures resembling more closely
the tissue of origin (41, 48, 49). However, one study revealed no
major gene expression profile differences in OVCAR-5 cells grown
in either 2D or 3D culture (50). The differences between these
studies may be due to cell line variability or variability in 3D
systems used.
Kenny et al. among other groups, have taken the 3D model a
step further and describe a 3D organotypic model of ovarian can-
cer metastasis, mimicking human peritoneum and omentum (35,
51). This model has the potential to advance our understanding of
invasion and metastasis, allowing researchers to work with a highly
physiologically relevant model. The 3D model can be assembled
to histologically mimic the in vivo situation, with primary human
omental mesothelial cells, primary human omental fibroblasts,
and primary ovarian tumor cells to create patient-specific biol-
ogy and drug treatment options ex vivo (35). As with all model
systems, there are advantages and disadvantages: the main dis-
advantages being that the primary cultures are usually viable for
only a short period of time (around 1 week) and that the 3D mod-
els lack vasculature, host immune cells, and other in vivo factors.
However, an in vitro 3D model of EOC represents a significantly
more complex experimental system than monolayer cell cultures
for analysis of tumorigenesis and development of new therapeutic
approaches.
In the next section, we will discuss the most relevant cur-
rent cell line models of platinum sensitivity and resistance in
HGS and how their development has aided our understanding
of chemoresistance.
CURRENT CELL LINE MODELS OF PLATINUM-SENSITIVE
AND -RESISTANT HGS CANCER
Several cell lines exist representing platinum-sensitive or -resistant
HGS cancers, derived from patient tumor or ascites prior to
chemotherapy/chemoresistance and following resistant relapse.
The best known of these are three sets of platinum sensitive
and clinically acquired platinum-resistant HGS cell lines estab-
lished by Langdon et al. (10). These cell lines were derived from
the ascites or pleural effusions of platinum-sensitive patients
and again following their relapse with platinum-resistant dis-
ease. These were the first sets of clinically acquired sensitive
and resistant HGSOC models and have become an important
resource in the study of chemoresponse and resistance EOC (52–
55). In two of the sets, ascites or pleural effusion was obtained
prior to chemotherapy (PEO14 and PEA1), with the other lines
derived from cells obtained either after chemotherapy (PEO1,
PEO4, PEO6, PEA2, and PEO23) or radiotherapy (PEO16). PEO1
cells, while derived following chemotherapy treatment, were done
so following chemosensitive relapse. Disappointingly, there have
been few paired cell line models that accurately depict acquired
resistance to chemotherapy. The laboratories of Mes-Masson and
colleagues have also established similar cell lines representing
platinum sensitive and clinically acquired resistance from the
same patient and have also generated further unpaired platinum-
sensitive and -resistant cell lines (13, 56). Table 1 shows the list of
available paired HGSOC cell lines that exist currently.
Cell line models of platinum sensitive and clinically acquired
platinum-resistant HGSOC have been used over the past decade
examine the hypotheses regarding clonal evolution of tumor het-
erogeneity and treatment failure in HGS cancer, and to develop
novel therapies to reverse resistance. Cooke et al. used multi-
plex fluorescent in situ hybridization and array CGH profiling
to characterize the Langdon et al. (10) cell line pairs of platinum-
sensitive and -resistant HGS disease and determined, in these three
cases, that platinum-resistant disease did not appear to evolve lin-
early from sensitive disease (3). Rather, their data implied that
both cell lines shared a common ancestor from an earlier stage in
tumor development. Due to the extent and type of genomic alter-
ations observed between the pairs, they proposed that platinum-
resistant disease arose from pre-existing resistant sub-clones that
were selected for during chemotherapy treatment (3). Subse-
quent research in our laboratory using these paired HGS cell lines
identified key drivers of chemoresistance including DNA-PKcs-
mediated activation of pro-survival AKT following treatment with
DNA-damaging platinum-based chemotherapy (55) and HDAC4-
regulated STAT1 deacetylation and activation following platinum
treatment of resistant cells but not sensitive ones (54).
In vitro platinum sensitive and resistant cell lines, derived artifi-
cially in the laboratory by continuous or regular repeated exposure
to increasing concentrations of platinum drugs, are widely used
to uncover and characterize drug-resistant mechanisms (57, 58).
While they have the advantages of being well-established, easy to
work with and have identified useful tumor biology, we suggest
that due to the non-physiological manner in which resistance is
created, they should not be used as a definitive model of platinum
resistance for clinical research. We performed a gene expression
profiling of clinically acquired resistance versus in vitro derived
resistance, in cell lines derived from the same patient. This analysis
showed very poor concordance in gene expression profiles between
the two models (54). Many other unpaired, clinically acquired
platinum-sensitive or -resistant EOC cell lines are available, and
Table 1 | Clinical characteristics of paired platinum sensitive and resistant HGSOC cell lines.
Cell line nomenclature Histology at diagnosis Treatment course Reference
PEO1/4/6 Poorly differentiated serous adenocarcinoma Cis-platinum/5-fluorouracil/chlorambucil (10)
PEO14/23 Well-differentiated serous adenocarcinoma Cis-platinum/chlorambucil (10)
PEA1/2 Poorly differentiated serous adenocarcinoma Cis-platinum/prednimustine (10)
OV2295/OV2295(R2)/TOV2295(R) Serous adenocarcinoma Cisplatin/topotecan (13)
Paclitaxel/carboplatin
Doxorubicin
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have been extensively studied but as is the limitation with immor-
talized cell line models, which inherently develop phenotypic and
genotypic alterations over time due to prolonged passaging, many
established cell lines do not adequately model the clinical condi-
tion they are intended to represent (59). Commonly used epithelial
ovarian cell line models such as the platinum-resistant SKOV3 cell
line and A2780 have come under the spotlight recently, with mul-
tiple studies suggesting that they are poor models of HGSOC (60,
61) as, at the molecular level, they do not closely resemble typical
HGS tumors. In a separate study examining drug sensitivity in
3D cultures, SKOV3 lines were shown to have hallmarks of clear
cell histology (47). However, limited as models of HGSOC, these
cell lines do have a utility as general models of ovarian cancer, for
example SKOV3 is a good model of AKT-driven ovarian cancer,
harboring an activating point mutation in PIK3CA (61). Signifi-
cant strides to re-characterize existing cell lines to allow informed
experimental design and interpretation of data have been made in
recent years. For instance, a panel of 32 reported ovarian cancer
cell lines has been systematically classified into their correct histo-
types with the aim of definitively identifying more reliable models
of clear cell ovarian cancer (60). These recent studies should be
taken into account when choosing an ovarian cancer cell line as a
model system.
It is clear that new initiatives are required to generate well-
annotated and -controlled models of HGS for the ovarian cancer
research community.
ALTERNATIVE MODELS OF IDENTIFYING TUMOR CELL
HETEROGENEITY IN HGS DISEASE
CIRCULATING TUMOR CELLS
The identification of significant tumor heterogeneity in HGS has
raised questions over how representative single biopsy sampling
of tumor material is. Alternative and/or complementary methods
and models for tumor identification and monitoring of tumor
burden are required. Over the last decade, the need for alternative
models has seen a focus on CTCs and the isolation and analysis
of CTCs in peripheral blood as a model of tumor characterization
and evolution. First detected in 1869 by Ashworth in the blood
of a patient with metastatic cancer, CTCs have been implicated
in the development of distant metastasis (62). Furthermore, the
potential prognostic role of CTCs has been demonstrated with the
number of CTCs at any given time in peripheral blood, in cer-
tain tumor types, e.g., breast (63), lung (64), and prostate (65),
predictive of disease progression, thus allowing for monitoring of
disease burden during therapy. Several different approaches have
emerged to isolate and identify CTCs, for example microfluidics
systems for detection of cytokeratin positive or negative CTCs
(66) or EpCAM positive CTCs (67–69), or PCR-based methods
for monitoring a panel of predefined genes in ovarian cancer (70,
71). However, there are a few key drawbacks to the detection of
CTCs in peripheral blood. First, the low number of CTCs present
in circulation makes the initial detection of tumor cells prob-
lematic. Second, the various methodologies employed to detect
CTCs may not be identifying all CTCs in circulation depend-
ing on the experimental approach. Methods using EpCAM as
the tumor cell selection marker will not detect sub-populations
of CTCs that have undergone EMT or lost EpCAM expression
by other mechanisms. Additionally, many CTC isolation meth-
ods use two-layer density-gradient centrifugation, thus leading to
potential isolation of peripheral blood mononuclear cells in addi-
tion to CTCs. Altered immune profiles of mononuclear cells could
bias PCR-based profiling of gene expression panels (72, 73). A
recent study investigating the predictive value of CTCs in newly
diagnosed and recurrent ovarian cancer patients was inconclusive,
showing no correlation with clinical characteristics or patient out-
comes (69), suggesting that more work is required to delineate the
prognostic value of CTCs in ovarian cancer while establishing a
robust system for CTC isolation. The attractiveness of the use of
CTCs as a form of “liquid biopsy” to establish a diagnosis and to
monitor cancer burden in patients undergoing therapy and thus a
model of disease progression or resistance must be carefully con-
sidered. Advances in methodology for reliable isolation of CTCs
represent a vital area for progress.
CIRCULATING TUMOR DNA
The last 2 years have seen the emergence of detection of circulat-
ing tumor DNA in plasma as a method of tracking the genomic
evolution of the tumor in response to therapy (74, 75). Ease of pro-
cessing and accessibility to samples makes this non-invasive system
an enticing prospect for detection of disease, monitoring of tumor
burden, and determining evolution of clonal heterogeneity. Whole
genome, exome, and targeted deep sequencing of plasma tumor
DNA as single or serial samples have demonstrated the validity of
this system (76, 77). In particular, the recent study by Murtaza et al.
tracked six patients with advanced breast, ovarian, or lung cancer
over 1–2 years. They performed exome sequencing on multiple
samples collected at different time points and observed changes
in copy number (both gains and losses) and gene-specific muta-
tions between samples. The somatic mutations found in plasma
prior to and after each treatment course were analyzed to identify
changes in mutation profiles that could be attributed to disease
progression and drug resistance (78). A further potential advan-
tage of this method, as with CTCs, is that it reduces samples bias
that may exist using single-site biopsy sampling as ctDNA is more
likely to represent the tumor genome from multiple tumor sites,
thus reducing the emphasis of future analyses on single sub-clones
that may not represent the most common tumor genome.
Such techniques for detecting CTCs and sequencing of ctDNA
from liquid biopsies (blood and plasma) are expected to become
commonplace and to be developed and validated for prognostica-
tion and patient stratification in future clinical trials without the
need for invasive diagnostic procedures.
CONCLUSION
It is becoming increasingly evident that in the study of cancer cells
and in particular examining drug resistance in HGSOC, more ex
vivo and relevant in vitro models must be developed that more
closely resemble the in vivo tumor environment, an opinion shared
by others in recent reviews (59, 79). To that end, one of the goals
of the European OCTIPS (Ovarian Cancer Therapy – Innovative
Models Prolong Survival) consortium is to establish new, paired
HGSOC cell lines derived from patients who are platinum sensitive
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at presentation but subsequently relapse, in an effort to delineate
the mechanisms behind the development of relapse and platinum
resistance in HGSOC and furthermore to develop new in vivo sys-
tems such as the relatively high throughput avian chorioallantoic
membrane (CAM) models (80) and patient-derived xenografts
(PDXs) (81), to advance novel therapies to combat chemoresis-
tance. A recent study highlighted the utility of the PDX model in
HGSOC, as platinum response in the PDXs echoed clinical out-
come (82), whereas Lokman et al. highlighted advantages of the
CAM system in cost, throughput, and reproducibility, compared
to mice, as an in vivo model for studying complex phenotypes in
ovarian cancer (83). Ideally, a consensus needs to be reached on
standardized protocols for the isolation of tumor cells from both
ascites and solid tumor or metastatic deposits, both in platinum-
sensitive and -resistant disease, and a standardized set of markers
that will definitively differentiate EOC tumor cells from contam-
inating stromal cells, such as cancer-associated fibroblasts. Such
efforts would ensure that the subsequent results and conclusions
drawn from experiments performed on these primary tumor cell
populations and subsequent immortalized tumor cells can be
confidently and correctly interpreted.
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